What is prognosis of Lung cancer?

['ⵙⵎⴷ ⵜⴰⴱⵔⴰⵜ ⴰⴷ']

ⵎⴰⵜⵜⴰ ⵉⴳⴰ ⵓⴱⵓⵔⵣ ⵏ ⵍⴽⵏⵚⵉⵔ ⵏ ⵓⵖⵢⵓⵍ?

ⴷⴰ ⵉⵜⵜⴱⴷⴷⴰ ⵓⵙⵏⵎⴰⵍ ⵏ ⵓⴽⵕⴰⵏⵚⵓ ⵏ ⵓⵖⵢⵉⵎ ⵅⴼ ⴽⵉⴳⴰⵏ ⵏ ⵉⵎⵙⴽⴰⵔⵏ, ⴳ ⵉⵍⵍⴰ ⵓⵙⵡⵉⵔ ⵏ ⵓⴽⵕⴰⵏⵚⵓ, ⴷ ⵡⴰⵏⴰⵡ ⵏ ⵓⴽⵕⴰⵏⵚⵓ ⵏ ⵓⵖⵢⵉⵎ, ⴷ ⵜⴷⵓⵙⵉ ⵜⴰⵎⴰⵜⵜⵓⵜ ⵏ ⵓⵎⵙⴳⵏⴰⴼ.

ⵉⵍⴰ ⵓⴽⵏⵙⵉⵔ ⵏ ⵓⵖⵢⵓⵍ ⵓⵔ ⵉⴳⵉⵏ ⴰⵎⵥⵥⵢⴰⵏ, ⵏⵏⴰ ⵉⴳⴰⵏ ⵡⴰⵏⴰⵡ ⵉⴳⴳⵓⵜⵏ, ⴰⵙⵖⵍ ⵏ ⵜⵓⴷⵔⵜ ⵏ 5 ⵉⵙⴳⴳⵡⴰⵙⵏ ⵏ 18% ⴳ ⴽⵓⵍ ⵉⴽⵏⵉⵡⵏ ⵙ ⵓⵙⵙⵎⵓⵏ.

ⵎⵇⵇⴰⵔ, ⵎⴽ ⴷⴰ ⵉⵜⵜⵓⵢⴰⵙⵙⵏ ⵓⴽⵏⵙⵉⵔ ⴳ ⵜⵉⵣⵉ ⵏⵏⵙ, ⵉⵖⵢ ⵓⵙⵖⵍ ⵏ ⵜⵓⴷⵔⵜ ⵏ 5 ⵏ ⵉⵙⴳⴳⵡⴰⵙⵏ ⴰⴷ ⵉⵍⴽⵎ 57%. ⵍⴽⵏⵙⵉⵔ ⵏ ⵓⵖⵢⵉⵎ ⵏ ⵜⵖⵔⴰⵙⵜ ⵜⴰⵎⵥⵥⵢⴰⵏⵜ, ⵏⵏⴰ ⵓⵔ ⴱⴰⵀⵔⴰ ⵉⵜⵜⵡⴰⵙⵙⵏ, ⵉⵍⴰ ⵓⵙⵖⵍ ⵏ ⵜⵓⴷⵔⵜ ⵏ 5 ⵏ ⵉⵙⴳⴳⵡⴰⵙⵏ ⵏ 7% ⴳ ⴽⵓⵍ ⵜⵉⵙⴽⴼⴰⵍ ⵙ ⵓⵙⵙⵎⵓⵏ.

Iⵂⴰ ⴰⴾⴰⵉⴰⴷ ⴰⵙ ⵓⵉⵏ ⴰⵈⵈⴰⵍⴰⵏ ⵉⵙⵜⴰⴱⴰⵜⴰⵏ ⵓⵉⵏ ⴰⵎⴰⵙⵏⴰⵙ ⴰⴷ ⵜⵉⴼⵉⴾⵉⵜⵢⵏ ⵜⵉⵏ ⴰⴷⴷⵉⵏⴰⵜ ⴰⴷⴷⵓⴱⴰⵜ ⴰⴷ ⵜⵉⵋⵉⵛⴰⵍⵢⵏ

ⴷⴰ ⵙⵓⵍ ⵜⵜⴱⵓⵖⵍⵓⵏ ⵉⵙⵜⴰⵢⵏ ⵏ ⵓⵙⵎⴽⵍ ⴷ ⵉⵙⴱⵓⵖⵍⵓⵜⵏ ⴳ ⵜⵙⵏⵉⵊⵊⵉⵜ, ⴷ ⴽⵉⴳⴰⵏ ⵏ ⵉⵎⴷⵢⴰⵡⵏ ⵖⵉⵏ ⴰⴷ ⴷⴷⵔⵏ ⵓⴳⴳⴰⵔ ⴷ ⴰⴷ ⵖⵓⵔⵙⵏ ⵢⵉⵍⵉ ⵓⵙⵖⵓⴷⵓ ⵏ ⵓⵙⵡⵉⵔ ⵏ ⵜⵓⴷⵔⵜ ⵙ ⵓⵃⵟⵟⵓ ⴷ ⵓⵙⵡⵓⴷⴷⵓ ⵉⵖⵓⴷⴰⵏ.

['ⵉⵙⵓⵎⴰⵔ']

PubMed/Medline https://www.nlm.nih.gov/databases/download/pubmed_medline.html

RefinedWeb https://arxiv.org/abs/2306.01116

Martini B: [Lung cancer--epidemiology, prognosis and therapy]. Med Monatsschr Pharm. 2006, 29 (6): 217-21.

Zou T, Liu JY, She L, Yin JY, Li X, Li XP, Zhou HH, Chen J, Liu ZQ: The Association Between Heat-Shock Protein Polymorphisms and Prognosis in Lung Cancer Patients Treated With Platinum-Based Chemotherapy. Front Pharmacol. 2020, 11 (): 1029.

Li L, Zhou Q, Luo D, Xu Y, Yang H, Zhang S, Li A, Li H, Lv C: [A study on the relationship between lung cancer cell apoptosis and prognosis in patients with human non-small cell lung cancer.]. Zhongguo Fei Ai Za Zhi. 1998, 1 (2): 70-3.

Feng YY, Yang Y, Wang YY, Bai XX, Hai P, Zhao R: [Hypomethylation of DAPL1 associated with prognosis of lung cancer patients with EGFR Del19 mutation]. Zhonghua Zhong Liu Za Zhi. 2021, 43 (12): 1264-1268.

Xiao Y, Zhu S, Yin W, Liu X, Hu Y: IGFBP-4 expression is adversely associated with lung cancer prognosis. Oncol Lett. 2017, 14 (6): 6876-6880.

Lang J, Zhao Q, He Y, Yu X: Bone turnover markers and novel biomarkers in lung cancer bone metastases. Biomarkers. 2018, 23 (6): 518-526.

['ⴰⵙⴱⴷⵉⴷ: ⴰⵎⵙⵏⵉⵊⵊⵉ']

['ⴰⵙⵉⵜ ⴰⴷ ⵉⵜⵜⵓⴼⴽⴰ ⵖⴰⵙ ⵉ ⵓⵡⵜⵜⴰⵙ ⵏ ⵓⵙⵙⵍⵎⴷ ⴷ ⵓⵙⵏⵖⵎⵙ, ⵓⵔ ⵉⴳⵉ ⴰⵙⴼⴽ ⵏ ⵓⵎⵛⴰⵡⴰⵕ ⵏ ⵓⴷⵓⵙⵜⵓⵔ ⵏⵖⴷ ⵜⵡⵓⵔⵉⵡⵉⵏ ⵜⵉⵣⵣⵓⵍⴰⵏⵉⵏ.']

['ⵓⵔ ⵉⵇⵇⵉⵏ ⴰⴷ ⵉⵜⵜⵓⵙⵎⵔⵙ ⵓⵎⵍⴰⵏ ⵉⵜⵜⵓⴼⴽⴰⵏ ⴳ ⵓⵙⵎⵔⵙ ⵏ ⵓⵙⵎⵉⴳⵍ ⵏⵖⴷ ⵓⵙⵓⵊⵊⵉ ⵏ ⵜⵎⵓⴽⵔⵉⵙⵜ ⵏ ⵜⴷⵓⵙⵉ ⵏⵖⴷ ⵜⵎⴰⴹⵓⵏⵜ, ⴷ ⵡⵉⵏⵏⴰ ⵉⵔⴰⵏ ⴰⵙⵇⵇⵙⵉ ⴰⵎⵙⵏⵉⵊⵊⵉ ⴰⵡⵏ ⵉⵜⵜⵓⴼⴽⴰⵏ ⵉⵇⵇⴰⵏ ⴰⴷ ⵙⴰⵡⵍⵏ ⴷ ⵓⵎⵙⵏⵉⵊⵊⵉ ⵉⵜⵜⵓⵥⵍⴰⵢⵏ.']

['ⵙ ⵡⴰⵍⵍⵍⵉ ⵉⵜⵜⵓⵢⴰⵏⵏⴰ, ⵜⴰⵔⴰⵜⵙⴰ ⵏ ⵓⵏⵢⵓⵔⴰⵍ ⵏⵏⴰ ⵉⵜⵜⴰⴽⴽⴰⵏ ⵜⵉⵎⵔⴰⵔⵓⵜⵉⵏ ⵉ ⵉⵙⵇⵙⵉⵜⵏ, ⵓⵔ ⴷⴰ ⵜⵜⵉⵍⵉ ⴰⴽⴽⵡ ⵜⵓⵙⴷⵉⴷⵜ ⴳ ⵎⴰⴷ ⵉⵥⵍⵉⵏ ⵙ ⵓⵡⵏⵖ ⵏ ⵓⵟⵟⵓⵏ. ⵙ ⵓⵎⴷⵢⴰ, ⵓⵟⵟⵓⵏ ⵏ ⵎⴷⴷⵏ ⵉⵜⵜⵓⵙⵏⴼⴰⵍⵏ ⵖⴼ ⵜⵎⴰⴹⵓⵏⵜ ⵉⵥⵍⵉⵏ.']

['ⵚⵓⴰⵍ ⵙⵓⵍ ⴰⵙⵏⴰⵍ ⵏ ⵓⵊⵉⵊⵊⵉ ⵏⵏⴽ ⵏⵖⴷ ⴽⵔⴰ ⵏ ⵓⵎⵙⵙⵉⵡⵍ ⵏ ⵜⴷⵓⵙⵉ ⵢⴰⴹⵏ ⵉⵇⴱⵍⵏ ⴳ ⵎⴰⴷ ⵉⵥⵍⵉⵏ ⵙ ⵡⴰⴷⴷⴰⴷ ⵏ ⵜⴷⵓⵙⵉ. ⵓⵔ ⴰⴽⴽⵡ ⴰⴷ ⵜⵙⵙⴼⵍⴷ ⴰⵙⵏⴰⵍ ⵏ ⵓⵊⵉⵊⵊⵉ ⴰⵣⵣⵓⵍⴰⵏ ⵏⵖⴷ ⴰⴷ ⵜⵣⴰⵢⴷ ⴳ ⵓⵙⵓⵜⴳ ⵏⵏⵙ ⴰⵛⴽⵓ ⵏⵜⵜⴰⵜ ⴰⵢⴷ ⵜⵙⵙⵖⵔⴷ ⴳ ⵓⵙⵉⵜ ⴰⴷ. ⵎⴽ ⵜⵓⵔⴷⴰ ⴰⴷ ⵖⵓⵔⴽ ⵉⵍⵍⴰ ⵡⴰⴷⴷⴰⴷ ⵏ ⵜⴷⵓⵙⵉ ⵉⵣⵣⴳⵔⵏ, ⵙⵎⴷ 911 ⵏⵖⴷ ⴰⴷ ⴷⵉⴷⵜ ⵜⴰⵍⵙ ⴷⴰⵔ ⵜⴰⴷⴰⵍⴰ ⵏ ⵓⵣⵣⵔⴰⵢ ⵏ ⵣⵉⴽⴽ. ⵓⵔ ⵜⵍⵍⴰ ⵜⵓⵇⵇⵏⴰ ⵏ ⵓⵊⵉⵊⵊⵉ ⴷ ⵓⵎⵏⵉⴳ ⵙ ⵓⵙⵉⵜ ⴰⴷ ⵏⵖⴷ ⵓⵙⵎⵔⵙ ⵏⵏⵙ. ⵓⵔ ⴷⴰ ⵜⵙⴽⴰⵔ ⴱⵢⵓⵎⵉⴷⵍⵉⴱ ⵏⵖⴷ ⵉⵎⵙⵡⵓⵔⵉⵏ ⵏⵏⵙ ⵏⵖⴷ ⴽⵔⴰ ⵏ ⵓⵎⴷⵔⴰⵡ ⴳ ⵓⵙⵉⵜ ⴰⴷ ⴽⵔⴰ ⵏ ⵓⵙⵎⴷⵢⴰ, ⵙ ⵡⴰⵡⴰⵍ ⵏⵖⴷ ⵙ ⵓⵙⵏⵓⵎⵍ, ⴳ ⵎⴰⴷ ⵉⵥⵍⵉⵏ ⵙ ⵉⵏⵖⵎⵉⵙⵏ ⵉⵍⵍⴰⵏ ⴳ ⵓⴷⵖⴰⵔ ⴰⴷ ⵏⵖⴷ ⵓⵙⵎⵔⵙ ⵏⵏⵙ.']

['ⴰⵙⴱⴰⴷⵓ: ⵉⵣⵔⴼⴰⵏ ⵏ ⵓⴼⵓⵙ']

['ⴰⵛⵔⵓⵜ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ']

['ⵎⴽ ⵜⵛⵛⵉⵖⴰⵍⴷ ⵙ ⵜⵛⵛⵉⵢⵜ ⵎⴰⵙⴷ ⴽⵔⴰ ⵏ ⵜⵓⵎⴰⵢⵜ ⵏⵖⴷ ⵉⵙⵏⴼⴰⵔⵏ ⵏⵏⴰ ⵉⵜⵜⵓⴼⴽⴰⵏ ⴳ ⵡⴰⵙⵉⵜ ⵏⵏⵓⵏ ⵏⵖⴷ ⵜⵉⵙⵏⵙⵉ ⵏⵏⵓⵏ ⴷⴰ ⵉⴽⵛⵎⵏ ⴳ ⵉⵣⵔⴼⴰⵏ ⵏ ⵓⵣⵔⴼ ⵏⵏⵓⵏ, ⵜⵣⵎⵔⴷ ⴰⴷ ⵜⴰⵍⵙⴷ (ⵏⵖ ⴰⵎⴷⵢⴰⵣ ⵏⵏⴽ) ⴰⴷ ⵜⵙⵏⵎⵍⴷ ⵉ ⵡⴰⵙⵉⵜ ⵏⵏⵓⵏ ⵙ ⵓⵙⵓⵜⵔ ⵏ ⵓⵙⵙⵉⴷⴼ ⵏ ⵜⵓⵎⴰⵢⵜ ⵏⵖⴷ ⵉⵙⵏⴼⴰⵔⵏ, ⵏⵖⴷ ⴰⴷ ⵜⴱⴷⴷⴷ ⵜⵉⵍⵉⵜ ⵏⵏⵙⵏ.']

['ⵉⵏⴰⵓⴰⵏ ⴰⵂⴰⵏ ⴰⴾⵜⴰⴱ ⵙ ⴰⵍⴾⵉⵜⵜⴰⴱ ⵙ ⵎⵢⵍ (ⵉⴾⵉⴰⴷ ⵙ ⴰⴾⵜⴰⴱ "ⵎⵢⵍ" ⵉ ⵎⵢⵍ)']

['DMCA ⵜⵙⵙⵓⵜⵔ ⴰⵙⵎⵉⵙⵉ ⵏⵏⴽ ⵏ ⵓⵎⴳⴰⵍ ⵏ ⵉⵣⵔⴼⴰⵏ ⵏ ⵓⵎⴳⴰⵢ ⵉⴽⵛⵎ ⴳ ⵓⵙⵎⵎⴰⵍ ⴰⴷ: (1) ⴰⵙⵏⵓⵎⵍ ⵏ ⵜⵡⵓⵔⵉ ⵉⵃⴱⴰⵏ ⵉⵣⵔⴼⴰⵏ ⵏ ⵓⵎⴳⴰⵢ ⵏⵏⴰ ⵉⴳⴰⵏ ⴰⵙⵏⵜⵍ ⵏ ⵓⵎⴳⴰⵍ; (2) ⴰⵙⵏⵓⵎⵍ ⵏ ⵜⵓⵎⴰⵢⵜ ⵉⵃⴱⴰⵏ ⵉⵣⵔⴼⴰⵏ ⴷ ⵉⵏⵖⵎⵉⵙⵏ ⵉⵅⵚⵚⴰⵏ ⴰⴼⴰⴷ ⴰⴷ ⵏⴰⴼ ⵜⵓⵎⴰⵢⵜ; (3) ⵉⵏⵖⵎⵉⵙⵏ ⵏ ⵓⵎⵢⴰⵡⴰⴹ ⴰⴽⴷⴽ, ⴳ ⵉⵍⵍⴰ ⵡⴰⵏⵙⴰ ⵏⵏⴽ, ⵓⵟⵟⵓⵏ ⵏ ⵜⵉⵍⵉⴼⵓⵏ ⴷ ⵡⴰⵏⵙⴰ ⵏ ⵓⵍⵉⴽⵜⵕⵓⵏ; (4) ⴰⵙⵉⵡⴹ ⵏⵏⴽ ⵎⴰⵙ ⴷⴰⵔⴽ ⵜⴰⵍⵍⵉⵍⵜ ⵉⵖⵓⴷⴰⵏ ⵏ ⵓⵙⵏⴽⴷ ⵎⴰⵙ ⵜⵓⵎⴰⵢⵜ ⵙ ⵜⵖⴰⵔⴰⵙⵜ ⵏⵏⴰ ⵜⵙⵙⵔⴳⴰⵍ ⵓⵔ ⵜⴽⴽⵉ ⵜⵓⵔⴰⴳⵜ ⵙⴳ ⵖⵓⵔ ⵡⴰⵏⵏⴰ ⵉⵟⵟⴰⴼⵏ ⵉⵣⵔⴼⴰⵏ ⵏ ⵓⵎⴳⴰⵢ, ⵏⵖⴷ ⴰⵎⴷⵢⴰⵣ ⵏⵏⵙ, ⵏⵖⴷ ⵙ ⵓⵙⵡⵓⵔⵉ ⵏ ⴽⵔⴰ ⵏ ⵓⵙⵍⴳⵏ; ']

['(5) ⴰⵙⵉⵙⵙⵉⴾⵉ ⵏⵢⵜ, ⵉⴾⴼⴰⵏ ⵙ ⴰⵍⵆⴰⴾⵓⵎ ⵏ ⴰⵍⵆⴰⴾⵓⵎ ⵏ ⵜⵉⴷⵉⵜ, ⴰⵙ ⵉⵙⴰⵍⴰⵏ ⵓⵉⵏ ⵢⵎⵢⵍ ⵏⴰⵙⴰⵏ ⵓⵉⵏ ⵢⵎⵢⵍ ⵓⵉⵏ ⴰⴾⴰⵉⴰⴷ ⴷ ⴰⵙ ⵉⵍⴰ ⴰⴾⴰⵉⴰⴷ ⵉ ⴰⵙⵓⵋ ⵏ ⴰⵍⵆⴰⴾⵓⵎ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵜⵉⵏ ⴰⴾⴰⵉⴰⴷ ⵓⵉⵏ ⴰⴾⴰⵉⴰⴷ ⵓⵉ ⴰⵋⵋⴰⵏⵢⵏ']

['ⴷ (6) ⴰⴾⴰⵔⵓⵙ ⵏ ⵉⴾⵉⵜⴱⴰⵏ ⵏ ⵎⵓⵙⵏⴰⵜ ⵏ ⵉⴾⵉⵜⴱⴰⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜ ⵎⵢⵗ ⵓⴰ ⵉⵋⵋⴰⵏ ⵙ ⵢⵎⵢⵍ ⵏ ⵎⵓⵙⵏⴰⵜ ⵏ ⵉⴾⵉⵜⴱⴰⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜ']

['ⴰⴾⴰⵉⴰⴷ ⵏ ⴰⵙⴰⴾⵏⵢ ⵏ ⵉⵙⴰⵍⴰⵏ ⵓⵉⵏ ⴰⵋⵋⵓⵜⵏⵢⵏ ⴰⴷⴷⵓⴱⴰⵜ ⴰⴷ ⵢⵈⵈⵉⵍ ⴰⵙⵉⵓⴰⴷ ⵏ ⴰⴾⴰⵉⴰⴷ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜ ⵏⵢⵜ']

['ⴰⵎⵢⴰⵡⴰⴹ']

['ⵙⵓⴾⵢⵍ ⵉⵢⵎⴰⵍ ⵉⵢⵎⴰ ⵙ ⴽⴰⴾⴰⵎⴰⵍ ⴰⵙⵉⵙⵜⴰⵏ/ⴰⵙⵓⵋ']

What is prognosis of lung cancer?

The prognosis of lung cancer depends on several factors, including the stage of the cancer, the type of lung cancer, and the overall health of the patient.

Non-small cell lung cancer, which is the most common type, has a 5-year survival rate of about 18% for all stages combined.

However, if the cancer is caught early, the 5-year survival rate can be as high as 57%. Small cell lung cancer, which is less common, has a 5-year survival rate of about 7% for all stages combined.

It is important to note that these are general statistics and individual outcomes may vary.

Treatment options and advancements in medicine continue to improve, and many patients can live longer and have a better quality of life with proper care and management.

Disclaimer: medical

This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.

The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.

Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.

Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.

Disclaimer: copyright

The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.

['ⴰⵜⵜⴰⵢⵏ']

['ⴷⴰ ⵉⵙⵙⵎⵔⴰⵙ ⴱⵢⵓ ⵎⵉⴷⵍⵍⵉⴱ ⵉⵎⴰⵙⵙⵏ ⵏ ⵓⵙⵉⴳⴳⵍ ⵉⵎⵉⴽⵙⵉⵍⵏ (ⴰⵍⴳⵓⵔⵉⵜⵎ ⵏ ⵓⵍⵎⵎⵓⴷ ⵏ ⵉⵎⵉⵙ) ⵉ ⵓⵙⵓⴼⵖ ⵏ ⵉⵎⵣⵉⵏⵏ ⵏ ⵉⵙⵇⵙⵉⵜⵏ ⴷ ⵜⵎⵔⴰⵔⵓⵜⵉⵏ.']

['ⴷⴰ ⵏⵙⵙⵏⵜⵉ ⵙ 35 ⵎⵍⵢⵓⵏ ⵏ ⵜⵥⵕⵉⴳⵉⵏ ⵏ ⵜⵙⵏⵉⵊⵊⵉⵜ ⵜⴰⴱⵢⵓⵎⵉⴷⵉⴽⵜ ⵏ ⴱⴰⴱⵎⵉⴷ/ⵎⵉⴷⵍⵉⵏ. ⵓⵍⴰ ⴰⵡⴷ ⵜⵉⴼⵔⴽⵉⵏ ⵏ ⵡⵉⴱ ⵏ ⵔⴰⴼⵉⵏⴷⵡⵉⴱ.']

['ⴰⵜ-ⵓ-ⴰⵗ "ⴰⵍⵓⴰⵈⴰⵏ" ⴰⴷ "ⴰⴾⴼⴰⵣ"']